Celastrol ameliorates atherosclerosis by inhibiting TLR4/STAT3/NLRP3-mediated macrophage pyroptosis
Yaning Shi, Ziyi Li, Qizhi Liu, Yun Qiu, Junpeng Long, Qiong Yang, Chanjuan Zhang, Yongzhen Gong, Li Qin · 2026
Read Celastrol ameliorates atherosclerosis by inhibiting TLR4/STAT3/NLRP3-mediated macrophage pyroptosis by Yaning Shi, Ziyi Li, Qizhi Liu, Yun Qiu, Junpeng Long, Qiong Yang, Chanjuan Zhang, Yongzhen Gong, Li Qin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13217949.txt.
Description
Yaning Shi and colleagues report in 2026 that celastrol, a compound from the root of the thunder god vine, slows atherosclerosis in mice. The disease builds fatty plaques inside arteries, and one driver is pyroptosis, an inflammatory form of cell death in macrophages, the immune cells inside plaques. The study tests whether celastrol can quiet that process.
The team combined a mouse model of atherosclerosis with cultured macrophages exposed to oxidized LDL, the cholesterol form that triggers pyroptosis. Celastrol reduced cell death in the dishes and eased plaque growth and instability in the animals. Tests of binding and signaling showed that celastrol blocks the receptor TLR4, which lowers STAT3 activation and in turn switches off the NLRP3 inflammasome that drives pyroptosis. The authors propose celastrol as a candidate drug for atherosclerosis, though all findings so far are preclinical.
Catalog record
| CREATOR | Yaning Shi, Ziyi Li, Qizhi Liu, Yun Qiu, Junpeng Long, Qiong Yang, Chanjuan Zhang, Yongzhen Gong, Li Qin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |